Luyan Pharmaceuticals: Announcement on Abnormal Fluctuations in the Company’s Stock Trading

Securities code: 002788 Securities abbreviation: Luyan Pharmaceuticals Announcement number: 2026-001

Luyan Pharmaceutical Co., Ltd.

Announcement on abnormal fluctuations in company stock trading

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

1. Abnormal fluctuations in stock trading

The stock trading price of Luyan Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has deviated from the closing price increase by more than 20% in two consecutive trading days (January 7, 2026, January 8, 2026). According to the relevant regulations of the Shenzhen Stock Exchange, it is a case of abnormal stock trading fluctuations.

2. The company pays attention to and verifies relevant situations

In response to the abnormal fluctuations in the company's stock transactions, the company has verified the relevant matters in accordance with the requirements of relevant regulations. The relevant situation is now explained as follows:

1. There is no need to correct or supplement the information disclosed in the previous period;

2. The company's recent operating conditions have been normal, and there have been no major changes in the internal and external operating environment;

3. The company is not aware of recent public media reports on undisclosed major information that may or has had a greater impact on the company’s stock trading price;

4. The company, controlling shareholders and actual controllers have no major matters that should be disclosed but have not been disclosed, or major matters that are in the planning stage;

5. During the period of abnormal stock fluctuations, the controlling shareholder and actual controller did not buy or sell the company's stocks.

3. There is no explanation that information should be disclosed but has not been disclosed

The company's board of directors confirms that the company currently does not have any undisclosed matters that should be disclosed in accordance with the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations, or any planning, negotiations, intentions, agreements, etc. related to the matter; the board of directors is also not informed that the company has undisclosed information that should be disclosed in accordance with the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations, which has a greater impact on the company's stock trading price; there is no need to correct or supplement the information previously disclosed by the company.

4. Risk warning

1. After self-examination, the company did not violate fair information disclosure.

2. The company solemnly reminds investors: "Securities Daily", "Securities Times" and cninfo.com (http://www.cninfo.com.cn) are the company's designated information disclosure media. All the company's information is subject to the information disclosed in the above media. Investors are requested to invest rationally and pay attention to risks.

3. The company will strictly comply with the provisions and requirements of relevant laws and regulations, conscientiously perform its information disclosure obligations, and do a good job in information disclosure in a timely manner.

Announcement is hereby made.

Board of Directors of Luyan Pharmaceutical Co., Ltd.

January 9, 2026